United States & Sun Pharma
12 shared events · Importance 5 · Last updated Jun 08, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Regulatory
United States: The United States>>> is the market where the United States — Food and Drug Administration>>> accepted the BLA for AVT16, potentially expanding biosimilar options for patients and healthcare providers.
Sun Pharma: Sun Pharma>>> is responsible for the commercialization of AVT16 under a partnership with Alvogen>>>, which could expand its product portfolio if approved.
Jun 08, 2026 · 11 articles
Business
United States: The United States>>> is the target market for the biosimilar applications, with the United States — Food and Drug Administration>>> (FDA) being the regulatory authority for approval.
Sun Pharma: Sun Pharma>>> is partnered with Alvogen>>> for the commercialization of AVT05 and AVT06. The resubmission of BLAs by Alvogen>>> is a positive development for Sun Pharma>>> as it moves closer to potentially commercializing these biosimilars.
Jun 04, 2026 · 10 articles
International
United States: Renewed tensions between the United States and Iran unsettled investor sentiment in Indian and other Asian equity markets.
Sun Pharma: Sun Pharma>>> was among the winners in the S&P BSE Sensex>>> firms, suggesting strength in the pharmaceutical sector.
Jun 04, 2026 · 19 articles
Business
United States: Three U.S. gambling regulators have commenced reviews into Sportradar, indicating potential regulatory scrutiny and impact on the company's operations within the United States.
Sun Pharma: Sun Pharma is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered $420 million.
Apr 23, 2026 · 383 articles
International
Sun Pharma: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
Business
United States: The class action lawsuit is filed in a district court within the United States, indicating the legal jurisdiction of the event.
Sun Pharma: Sun Pharma is mentioned as a past success for Bleichmar Fonti & Auld LLP, where the firm recovered $420 million. This is a historical reference and not directly related to the current event.
May 18, 2026 · 236 articles
NEWSDESK
Explore this relationship live
Track how United States and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard